[Influence of chemosensional disorders on taste preferences in cancer patients who are receiving oral nutrition supplements].

Chemosensory disorders (CSD) such as disorders of taste and smell are one of the causes of malnutrition in cancer patients. The aim of the research was to evaluate the influence of CSD on taste preferences in cancer patients receiving oral nutritional supplements (ONS). Material and methods. The procedure involves 100 oncological patients (26 men, 74 women; 57.0±1.2 years old). The taste preferences in these patients were assessed using a digital rating scale during ONS. All patients had cancer outside the head and neck area and underwent specific treatment. The functional status on the ECOG scale was 0-II. All patients had indications for DPP (ESMO scale >2 points). Patients were offered a mixture of sweet (banana, coffee, vanilla) and unsweetened (vegetable, chicken soup) tastes in a disposable 30 ml container. The patient was asked to take a sip and evaluate the smell, taste, strength of taste and density (consistency) of the sample on a digital rating scale from 0 to 5 points, where 0 - I do not feel, 5 - I feel excellent. The maximum possible number of points for each sample was 20. Results. Signs of CSD (score <10) were detected in 69% of patients [95% confidence interval (CI) 59.5-77.7]. In this group, the frequency of choosing unsweetened tastes for ONS was 59.4% (95% CI 47.5-70.8), sweet - 40.6% (95% CI 29.2-52.5). In the group of patients without signs of CSD, the frequency of choosing savory tastes was 29.0% (95% CI 14.1-46.7), sweet - 71.0% (95% CI 53.3-85.9) (р=0.0049). Conclusion. The presence of CSD significantly affects the taste preferences of cancer patients and significantly increases the likelihood of choosing products for ONS with unsweetened taste (unsweetened foods).

Experimental induction of reparative morphogenesis and adaptive reserves in the ischemic myocardium using multipotent mesenchymal bone marrow-derived stem cells.

INTRODUCTION: Current experimental research has proven the efficacy of transplantation bone marrow-derived mesenchymal stem cells (MSC) in the treatment of myocardial infarction (MI). The one of the main purposes of research was to evaluate the comparative data of the MSC transplantation with (5-azacytidine) and without commitment and to assess the post transplantation effects. METHODS: The efficiency of intravenous cardiomyoplasty by infusion of MSC was evaluated in female Wistar-Kyoto rats with myocardial infarction model using echocardiography, morphological study, morphometry, immunohistostaining, data from in situ hybridization, and by measurement of blood serum levels of nitric oxide, endothelin-1, vascular endothelial growth factor (VEGF), and fibroblast growth factor 2 (FGF2). RESULTS: The transplanted MSC were detected in all layers of the myocardium; MCS actively participate in the formation of blood vessels and connective tissue in the scar zone. There was no observable differentiation of male MSC into cardiomyocytes in female rats with MI. However, MSC transplantation leads to significant improvement in vascularization in the area of MI, elevation blood serum levels of nitric oxide, VEGF, and FGF2. No significant differences were identified morphologically between the two groups of animals after transplantation with unmodified MSC or commited MSC (5-azaC). CONCLUSION: Intravenous transplantation of MSC without commitment in rats with MI improves the contractile function of the heart, the morphology of the myocardium, and should be recommended for further clinical investigation as an alternative approach to deal with heart diseases.